Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α

Blood

Volumn 104, Issue 7, 2004, Pages 1979-1988

  Kantarjian, Hagop M ^a   Cortes, Jorge E ^a   O'Brien, Susan ^a   Luthra, Rajyalakshmi ^a   Giles, Francis ^a   Verstovsek, Srdan ^a   Faderl, Stefan ^a   Thomas, Deborah ^a   Garcia Manero, Guillermo ^a   Rios, Mary Beth ^a   Shan, Jianqin ^a   Jones, Dan ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMATINIB;

ADULT; ANEMIA; ARTHRALGIA; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; LEUKEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; SIDE EFFECT; SPLENOMEGALY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 4644359704     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-02-0711     Document Type: Review

References (53)

1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia: current status and investigational options. Science. 1990;274:824-830.
2. Kelliher M, McLaughlin J, Witte O, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and bcr/abl. Proc Natl Acad Sci USA. 1990;87:6649-6653.
3. Hansen JA, Gooley TA, Martin PJ. et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962-968.
4. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet. 1998;352:1087-1092.
5. Goldman JM, Szydlo R, Morowitz MM, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood. 1993;82:2235-2238.
6. Beatty P, Anasetti C, Hansen J, Longton G, Sanders, J, Martin P. Bone marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. N Engl J Med. 1998;338:962-968.
7. Kantarjian HM. Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med. 1995;122:254-261.
8. Kantarjian HM, O'Brien S, Smith TL, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of Interferon alpha and low-dose cytarabine. J Clin Oncol. 1999;17:284-292.
9. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia. Blood. 1998;92:1541-1548.
10. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst. 2001;89:1616-1620.
11. Guilhot F, Chastang C, Michailet M, et al. Interferon alfa-2b combined with cytarabine versus Interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337:223-229.
12. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Monitoring treatment and survival in chronic myeloid leukemia. J Clin Oncol. 1999;17:1858-1868.
13. Faderl S. Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia; biology and therapy. Ann Intern Med. 1999;131-207-219.
14. Mahon F, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia-like syndrome in mice with v-abl and BCR/ABL. J Clin Oncol. 2003;20:214-220.
15. Bonifazi F, de Vivo A, Gianantonio R, et al. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood. 2001;98:3074-3081.
16. Kantarjian H, O'Brien S, Cortes J, et al. Complete cytogenetic and molecular responses to interferon-α based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97:1033-1041.
17. Druker B, Tamura S, Buchduner E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
18. Beran M, Cao X, Estrov Z, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-7148). Clin Cancer Res. 1998;4:1661-1672.
19. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of specific inhibitor of the BCR-ABL tyrosine in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
20. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
21. Kantarjian H, Sawyers CL, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
22. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
23. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
24. Kantarjian H, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadelphia-chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: follow-up results. Clin Cancer Res. 2002;8:2177-2187.
25. Kantarjian HM, O'Brien S, Cortes JE, et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002;8:2167-2176.
26. Kantarjian H, O'Brien S, Cortes J, et al. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-α failure and in late CML-CP, comparison with historical controls. Clin Cancer Res. 2004;10:68-75.
27. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
28. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101:97-100.
29. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446.
30. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis: an analysis of 242 patients. Am J Med. 1987;83:445-454.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
32. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
33. Cox DR. Regression models and life tables [with discussion]. J R Stat Soc B. 1972;34:187-220.
34. Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003;9:160-166.
35. Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood. 2000;95:62-66.
36. Paschka P, Muller M, Merx K, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon-alpha. Low levels of residual disease are associated with continuous remission. Leukemia. 2003;17:1687-1694.
37. Hughes T, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.
38. Marin D, Marktel S, Bua M, et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia. 2003;17:1448-1453.
39. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873-2878.
40. Kantarjian H, Talpaz M, O'Brien S, et al. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003;97:2225-2228.
41. Li Z, Qiao E, Laska J, et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein 70 vaccine for chronic myelogenous leukemia [abstract 664]. J Clin Oncol. 2003;22:166.
42. Bocchia M, Gentili S, Abruzzese E, et al. Imatinib plus CMLVAXlOO (P210-derived multipeptide vaccine): induction of complete molecular responses in patients with chronic myeloid leukemia (CML) showing persistent residual disease during treatment with imatinib mesylate [abstract]. Blood. 2003;102:30a.
43. Marin D, Ranger A, Kaeda J, et al. Phase I/II trial of adding semi-synthetic homoharringtonine (hht, myelostat) in CML patients who have achieved complete cytogenetic response on imatinib [abstract]. Blood. 2003;102:908a.
44. Cortes J, Talpaz M, O'Brien S, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003;98:1105-1113.
45. Cortes J, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101:3794-3800.
46. O'Dwyer M, Mauro M, Blasdel C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood. 2004;103:451-455.
47. Marin D, Marktel S, Szydlo R, et al. Survival of patients with chronic-phase myeloid leukaemia on imatinib after failure on interferon alfa. Lancet. 2003;362:617-619.
48. Hughes TP, Branford S, Matthews J, et al. Trial of higher dose imatinib with selective intensification in newly diagnosed CML patients in the chronic phase [abstract]. Blood. 2003;102:31a. Abstract 95.
49. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473-475.
50. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000;95:3498-3505.
51. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96:1070-1079.
52. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelsoh inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000;95:1758-1766.
53. Rosti G, Martinelli G, Bassi S, et al, for the Study and Writing Committee of the Italian Cooperative Study Group [ICSG] on Chronic Myeloid Leukemia. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood. 2004;103:2284-2290.